Menu Search
Equities

SciClone Pharmaceuticals (Holdings) Ltd

SCCPF:PKC

SciClone Pharmaceuticals (Holdings) Ltd

Actions
  • Price (USD)0.8301
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 07 2023.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SciClone Pharmaceuticals Holdings Ltd is a China-based biopharmaceutical company principally engaged in developing and commercializing a portfolio of marketed products as well as pipeline with potential in its focused therapeutic areas including oncology and severe infection. The Company primarily engages in the sales of its proprietary product, Zadaxin, its in-licensed products and promotion products on behalf of its business partners in China.

  • Revenue in HKD (TTM)3.39bn
  • Net income in HKD1.21bn
  • Incorporated2020
  • Employees1.05k
  • Location
    SciClone Pharmaceuticals (Holdings) Ltd22/FCentral Plaza, 381 Middle Huaihai RoadSHANGHAI ChinaCHN
  • Websitehttps://www.sciclone.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.